Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Advanced Gastric or GEJ Adenocarcinoma
NCT07327229Phase 2Recruiting
- Sponsor
- Antengene
- Start
- Feb 2026
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ATG-022 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Antengene. Started Feb 2026; status: recruiting.
02
Drugs
ATG-022
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07327229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07327229.